The reduction of our net loss in 2025 from 2024 was primarily related to the LifeSci Capital LLC judgment expense and reimbursement of legal costs, clinical trial related settlement expenses with A-IR ...

REVB READ THE FULL REVB RESEARCH REPORT Revelation Biosciences (NASDAQ: REVB) is a potentially high-upside clinical-stage biotechnology company focused on immune modulation and inflammatory disease ...

Revelation Biosciences (REVB) announced safety and activity data for its Phase 1b PRIME clinical study in stage 3 and 4 chronic kidney disease patients. The primary endpoint to evaluate the safety and ...

SAN DIEGO--(BUSINESS WIRE)--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on harnessing the power of trained ...

The randomized, double-blind, placebo-controlled trial will assess dosing regimens in Part 1 before moving into a Phase 3 study in Part 2. Revelation on Wednesday stated that the University of Florida ...